Filter By Industry
Filter By Tag

Press Room

Immune Response BioPharma, Inc. Press releases

1 - 10 of 10 Press Releases

Jul 07, 2015
Immune Response BioPharma, Inc., Provides FDA BLA Update Remune Likely to Carry Black Box Warning Label & U.S.A. Availability Only

Jun 17, 2015
(PR.com)-- Immune Response BioPharma, Inc., today provides an update on Remune and announces the FDA has accepted the Remune HIV/AIDS vaccine BLA (biologics licensing application) for review for therapeutic treatment in adults with HIV/AIDS.

Mar 27, 2015
Immune Response BioPharma, Inc., Today provides an update on REMUNE and announces the FDA has accepted the REMUNE HIV/AIDS vaccine BLA (biologics licensing application) for review for therapeutic treatment in adults with HIV/AIDS.

Feb 10, 2015
Immune Response BioPharma, Inc. Announces REMUNE FDA BLA Assignment PDUFA Goal date of December 22nd 2015 for Therapeutic HIV/AIDS Vaccine

Jan 01, 2015
Immune Response BioPharma, Inc. Posts 2nd Half and Full Year 2014 Results Finishing the Year Strong with REMUNE HIV/AIDS Vaccine BLA FDA Filing

Dec 20, 2014
Immune Response BioPharma, Inc. Files BLA with the FDA for REMUNE HIV/AIDS Vaccine Marketing Approval for Therapeutic HIV/AIDS Vaccination

Mar 21, 2014
Immune Response BioPharma, Inc. Announces NeuroVax Granted Fast Track FDA Designation for SPMS

Feb 18, 2014
Immune Response BioPharma, Inc. Announces its Flagship HIV/AIDS Vaccine REMUNE Granted Orphan Designation for Pediatric HIV/AIDS Therapeutic Vaccination by the FDA.

Feb 09, 2014
Immune Response BioPharma, Inc. Announces its Flagship Vaccine NeuroVax Granted Orphan Designation for Pediatric MS by the FDA.

Oct 31, 2012
Immune Response BioPharma, Inc. Publishes Phase III Full 806 Study Results, REMUNE Very Effective Demonstrating 0.7% HIV Progression vs 6% Estimated Rate & Subgroup Median Virologic Failure Delayed by 20 Weeks In REMUNE Group.


RSS Feed for Immune Response BioPharma, Inc. Press Releases